AdvaMed To Plead With USTR To Spare Medtech In China Tariffs
Executive Summary
In prepared remarks shared with Medtech Insight, AdvaMed plans to argue that tariffs imposed on medtech products made in China would disrupt an ongoing "action plan" the industry is pursuing to achieve reciprocal market access between the US and China for the industry.
You may also be interested in...
Industry Gives US Trade Rep 12 Reasons Why Tariffs on Chinese Medtech Imports Are A Bad Idea
The US Trade Representative office's decision in March to include devices, imaging machines and diagnostics on a list of Chinese imports destined for a 25% tariff has riled up the industry. A half-dozen medtech organizations protested the move in comments and testimony this week, supplying USTR with 12 reasons why the tariffs are a very bad idea.
US Tariffs On China Goods Also Target Diagnostics; Industry Preps For USTR Hearing
As more is learned about China-made medtech products facing a potential 25% US tariff, AdvaMed says some diagnostics would also take a hit and is working with its members to prepare for the upcoming US Trade Representative's public hearing on the impacts.
US Trade Rep Recommends Tariffs On China-Sourced Medtech, BioPharma Products
In addition to taxing foreign-made steel imports from certain countries, the US Trade Representative's office will soon recommend tariffs against Chinese-made biopharma and advanced medtech products, and other products in US/China competitive industries.